deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02023333

Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Sponsor: Bayer

Conditions Metastatic Colorectal Adenocarcinoma
Interventions Regorafenib
Updated 17 times since 2017 Last updated: Aug 26, 2025 Started: Dec 10, 2013 Primary completion: Aug 26, 2025 Completion: Aug 26, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Colorectal Adenocarcinoma, this trial is completed. The trial is conducted by Bayer and has accumulated 17 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Feb 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Memorial Sloan Kettering Cancer Center
  • Queens Cancer Center of Queens Hospital
  • State University of New York - Downstate Medical Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations